TRex Bio, a clinical-stage biopharma focused on autoimmune and inflammatory diseases, has filed for a U.S. IPO to raise capital for its drug development programs. Its lead candidate is in Phase 1b trials for atopic dermatitis, and the company benefits from a strong partnership with Eli Lilly, including milestone payments and potential IPO participation. Well-capitalized with diverse investors, TRex Bio aims to advance its pipeline targeting large markets but will need additional funding beyond the IPO. This move positions the company for future growth and value creation in the biopharma sector.
TRex Bio's IPO filing is the subject, with Pluang's health sector data providing market context. Of 100 health-sector US stocks on Pluang, 48 rose and 49 fell as of Sep 24, 2026 23:17 WIB. Notable movers include Twist Bioscience Corp at USD 171.67 with an 8.33% gain and 10X Genomics Inc at USD 81.50 with a 7.78% gain.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
